SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-030016
Filing Date
2023-08-21
Accepted
2023-08-18 18:11:30
Documents
13
Period of Report
2023-08-21
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K blcm-20230821.htm   iXBRL 8-K 30132
  Complete submission text file 0001628280-23-030016.txt   186476

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT blcm-20230821.xsd EX-101.SCH 2158
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT blcm-20230821_def.xml EX-101.DEF 14823
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT blcm-20230821_lab.xml EX-101.LAB 28857
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT blcm-20230821_pre.xml EX-101.PRE 15465
7 EXTRACTED XBRL INSTANCE DOCUMENT blcm-20230821_htm.xml XML 2731
Mailing Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098
Business Address 3730 KIRBY DRIVE SUITE 1200 HOUSTON TX 77098 (832) 384-1100
BELLICUM PHARMACEUTICALS, INC (Filer) CIK: 0001358403 (see all company filings)

IRS No.: 201450200 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36783 | Film No.: 231186914
SIC: 2834 Pharmaceutical Preparations